Mesenchymal Stem Cells Ameliorate Renal Inflammation in Adriamycin-induced Nephropathy
- Author:
Hyung Sook KIM
1
;
Jae Seob LEE
;
Hong Kyung LEE
;
Eun Jae PARK
;
Hye Won JEON
;
Yu Jeong KANG
;
Tae Yong LEE
;
Kyung Suk KIM
;
Sang Cheol BAE
;
Ji Hyun PARK
;
Sang Bae HAN
Author Information
- Publication Type:Brief Communication
- Keywords: Mesenchymal stem cells; Inflammation; Podocytes; Fibrosis
- MeSH: Actins; Animals; Body Weight; Chitinase; Collagen; Creatinine; Doxorubicin; Fibronectins; Fibrosis; Inflammation; Mesenchymal Stromal Cells; Mice; Podocytes; Proteinuria
- From:Immune Network 2019;19(5):e36-
- CountryRepublic of Korea
- Language:English
- Abstract: Mesenchymal stem cells (MSCs) ameliorate the renal injury in Adriamycin (ADR)-induced nephropathy, but the mechanisms underlying their efficacy remain incompletely understood. In this study, we demonstrated that MSCs increased the survival, recovered body weight loss, and decreased proteinuria and serum creatinine levels in ADR-treated mice. MSCs also prevented podocyte damage and renal fibrosis by decreasing the expression of fibronectin, collagen 1α1, and α-smooth muscle actin. From a mechanistic perspective, MSCs inhibited renal inflammation by lowering the expression of CCL4, CCL7, CCL19, IFN-α/β, TGF-β, TNF-α, and chitinase 3-like 1. In summary, our data demonstrate that MSCs improve renal functions by inhibiting renal inflammation in ADR-induced nephropathy.
